(Report ID: 174042) Many drug interactions and side effects can not be detected until the drugs have been used by millions of people, and for a long time. Large, long-term drug safety studies are ideal to discover these real-world drug outcomes. For the first time, eHealthMe enables health professionals and patients to conduct these studies for their drugs. Click here to check your drugs now, in a whole new way. As of Nov, 20, 2008, eHealthMe analyzes 10,180,582 drug interactions and side effects of 21,667 FDA-approved drugs from 1977 to the present. Results on Nov, 20, 2008: 2,221 relevant incidents
Note:
- The incidents can not include all actual occurrences
- Data of 2008 is not complete
DISCLAIMER: All adverse drug reaction material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only, and has not been supported by scientific studies or clinical trials unless otherwise stated. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk. Basic information:
| Report ID | Date of submission | Patient age | Patient gender |
| 174042 | Jul, 27, 2006 | 61 | Female |
List of drugs the patient takes:
| Name |
Nephrogenic Fibrosing Dermopathy |
Results from eHealthMe: 2,221 relevent incidents1) Comparison with the patient's adverse outcomes:
| Name | Count (% of total reports) |
Nephrogenic Fibrosing Dermopathy | 192 (8.64%) |
Death: 10 (1.98% of total reports)
Cancer: 0
| Name | Count (% of total reports) |
1 | Nephrogenic Systemic Fibrosis | 134 (26.59%) |
2 | Urticaria | 81 (16.07%) |
3 | Nausea | 73 (14.48%) |
4 | Pain | 59 (11.71%) |
5 | Dyspnoea | 57 (11.31%) |
6 | Injury | 52 (10.32%) |
7 | Pruritus | 50 (9.92%) |
8 | Anxiety | 45 (8.93%) |
9 | Vomiting | 45 (8.93%) |
10 | Emotional Distress | 41 (8.13%) |
3) Top co-used drugs drugs reported for the past 12 months:
| Name | Count |
1 | Omniscan | 133 |
2 | Optimark | 70 |
3 | Multihance | 57 |
4 | Prohance | 47 |
5 | Renagel | 19 |
6 | Coumadin | 17 |
7 | Epogen | 17 |
8 | Neurontin | 15 |
9 | Lipitor | 14 |
10 | Prilosec | 10 |
Death: 34 (1.53% of total reports)
Cancer: 3 (0.14% of total reports)
| Name | Count (% of total reports) |
1 | Dyspnoea | 268 (12.07%) |
2 | Nausea | 266 (11.98%) |
3 | Nephrogenic Systemic Fibrosis | 223 (10.04%) |
4 | Nephrogenic Fibrosing Dermopathy | 192 (8.64%) |
5 | Urticaria | 163 (7.34%) |
6 | Vomiting | 147 (6.62%) |
7 | Pruritus | 133 (5.99%) |
8 | Cough | 104 (4.68%) |
9 | Contrast Media Reaction | 99 (4.46%) |
10 | Anaphylactic Shock | 92 (4.14%) |
| Name | Count |
1 | Omniscan | 218 |
2 | Epogen | 95 |
3 | Coumadin | 91 |
4 | Multihance | 78 |
5 | Optimark | 78 |
6 | Aspirin | 76 |
7 | Neurontin | 68 |
8 | Renagel | 65 |
9 | Prohance | 59 |
10 | Lipitor | 49 |
Want to have a risk analysis report like this for your drugs? Click here. ADVERTISEMENT
----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- Recent drug risk analysis reports:
|
|
|
 |
|
How to use the report?
Bring a copy of this report to a doctor's appointment to ensure drug risks are fully discussed and understood, in the process of risk and benefit assessment.
|
 |
|
ADVERTISEMENT
|
|
